Herbal reference standards: Applications, definitions and regulatory requirements

Revista Brasileira de Farmacognosia

Volumn 23, Issue 1, 2013, Pages 1-21

  Zöllner, Tina ^a   Schwarz, Michael ^a  

^a PhytoLab GmbH   (Germany)

Author keywords

Brazilian herbal regulations; Dietary and food supplements; Herbal medicinal products; Phytochemical markers; Quality control; Reference substances

Indexed keywords

HERBACEOUS AGENT; PYRROLIZIDINE ALKALOID; STEVIOL;

ARTICLE; BOOK; BRAZIL; DRUG PURITY; EASTERN EUROPE; GAS CHROMATOGRAPHY; HEALTH CARE ORGANIZATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IDENTITY; QUALITY CONTROL; STANDARD; ULTRAVIOLET SPECTROSCOPY; WATER CONTENT;

EID: 84874520857     PISSN: 0102695X     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0102-695X2012005000144     Document Type: Article

References (56)

1. Anvisa 2010. Farmacopeia Brasileira 5a edicão. Agência Nacional de Vigilância Sanitária, http://www.anvisa.gov.br/hotsite/cd_farmacopeia/index.htm, accessed in Dec 2012.
2. Anvisa 2012. Agência Nacional de Vigilância Sanitária. http://www.anvisa.gov.br/eng/index.htm, accessed in Dec 2012.
3. Belz S, Wippo U, Nopitsch-Mai C 2010. Anforderungen an Referenzstandards chemisch definierter Substanzen aus regulatorischer Sicht. Pharm Ind 72: 2037-2042.
4. Bundesinstitut für Arzneimittel und Medizinprodukte 1996. Bekanntmachung über die Zulassung von Arzneimitteln durch das Bundesinstitut für Arzneimittel und Medizinprodukte (Neuer Formularansatz für den Antrag auf Zulassung eines Arzneimittels beim Bundesinstitut für Arzneimittel und Medizinprodukte) vom 31. Oktober 1996, Anhang 6. Bundesanzeiger 49: 53.
5. Diehl BWK, Malz F, Holzgrabe U 2007. Quantitative NMR spectroscopy in the quality evaluation of active pharmaceutical ingredients and excipients. Spectrosc Eur 19: 15-19.
6. EFSA Panel on Contaminants in the Food Chain (CONTAM) 2011. Scientific opinion on Pyrrolizidine alkaloids in Food and Feed. http://www.efsa.europa.eu/de/efsajournal/doc/2406.pdf, accessed in Dec 2012.
7. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims. http://www.efsa.europa.eu/en/efsajournal/doc/2135.pdf, accessed in Dec 2012.
8. EFSA Panel on Food Additives and Nutrient Sources (ANS) 2010. Scientific Opinion on the safety of steviol glycosides for the proposed uses as a food additive. http://www.efsa.europa.eu/de/efsajournal/doc/1537.pdf, accessed in Dec 2012.
9. th International Symposium on Pharmaceutical Reference Standards. Strasbourg, France. http://www.edqm.eu/site/session_3_material_management_technology_changes_p1pdf-en-30992-2.html, accessed in Dece 2012.
10. European Commission 1998. Guidelines: Medicinal Products for Human Use: Rules Governing Medicinal Products in the European Union: Guidelines Vol 3, 1998 (Rules Governing Medicinal Products in the European Union, Vol 3a,3b&3c). European Commission.
11. European Commission 2011. Commission Regulation (EU) No 1131/2011 of 11 November 2011 amending Annex II to Regulation (EC) No 1333/2008 of the European Parliament and of the Council with regard to steviol glycosides. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:295:0205:0211:EN:PDF, accessed in Dec 2012.
12. th Edition (7.5). European Directorate for the Quality of Medicines & HealthCare, http://www.edqm.org, accessed in Dec 2012.
13. European Food Safety Authority 2009. Guidance on Safety Assessment of Botanicals and Botanical Preparations intended for use as Ingredients in Food Supplements. http://www.efsa.europa.eu/de/scdocs/doc/1249.pdf, accessed in Dec 2012.
14. EMA 1995. Note for Guidance on Validation of Analytical Procedures: Text and Terminology (CPMP/ICH/381/95). European Medicines Agency, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002662.pdf, accessed Dec 2012.
15. European Medicines Agency 2000a. Note for Guidance Specifications: Test Procedures and Acceptance Criteria for new Drug Substances and new Drug Products. Chemical substances (CPMP/ICH/367/96). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002823.pdf, accessed in Dec 2012.
16. European Medicines Agency 2000b. Note for Guidance on Good Manufacturing Practice for Active Pharmaceutical Ingredients (CPMP/ICH/4106/00). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002825.pdf, accessed in Dec 2012.
17. European Medicines Agency 2006a. Guideline on Quality of Herbal Medicinal Products/Traditional Herbal Medicinal Products (CPMP/QWP/2819/00 Rev 1). http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003370.pdf, accessed in Dec 2012.
18. European Medicines Agency 2006b. Guideline on Specifications: Test Procedures and Acceptance Criteria for Herbal Substances, Herbal Preparations and Herbal Medicinal Products/Traditional Herbal Medicinal Products (CPMP/ QWP/2820/00 Rev 1). http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003393.pdf, accessed in Dec 2012.
19. European Medicines Agency 2008. Reflection Paper on Markers used for Quantitative and Qualitative Analysis of Herbal Medicinal Products and Traditional Herbal Medicinal Products (EMEA/HMPC/253629/2007). http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003196.pdf, accessed in Dec 2012.
20. European Parliament and the Council of the European Union 2004. Directive 2004/9/EC on the Inspection and Verification of Good Laboratory Practice (GLP). http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2004:050:0028:0043:EN:PDF, accessed in Dec 2012.
21. FDA 1999. Guidance for Industry. Validation of Analytical Procedures: Methodology. Food and Drug Administration http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/ucm052379.pdf, accessed in Dec 2012.
22. FDA 2004. Guidance for Industry - Botanical Drug Products. Food and DrugAdministration, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070491.pdf, accessed in Dec 2012.
23. FDA 2012. Code of Federal Regulations Title 21, Part 111. Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. Food and Drug Administration, http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?CFRPart=111, accessed in Dec 2012.
24. Hansen JR, De Oliviera BH 1993. Stevioside and related sweet diterpenoid glycosides. Nat Prod Reports 10: 301-309.
25. Helliwell K 2006. Herbal Reference Standards. Pharmeuropa 2: 235-238.
26. International Organisation for Standardization, 1997. Guide 32 - Calibration in Analytical Chemistry and Use of Certified Reference Materials. ISO copyright office, Geneva, Switzerland.
27. International Organisation for Standardization, 2000a. Guide 31 - Reference Materials - Contents of Certificates and Labels. ISO copyright office, Geneva, Switzerland.
28. International Organisation for Standardization, 2000b. Guide 33 - Uses of Certified Reference Materials. ISO copyright office, Geneva, Switzerland.
29. International Organisation for Standardization, 2006. Guide 35 - Reference Materials - General and Statistical Principles for Certification. ISO copyright office, Geneva, Switzerland.
30. International Organisation for Standardization, 2008. Guide 30/ Amd. 1 - Revision of Definitions for Reference Material and Certified Reference Material. ISO copyright office, Geneva, Switzerland.
31. International Organisation for Standardization, 2009. Guide 34 - General Requirements for the Competence of Reference Material Producers. ISO copyright office, Geneva, Switzerland.
32. JECFA 2010. Steviol Glycosides. http://www.fao.org/ag/agn/jecfa-additives/specs/monograph10/additive-442-m10.pdf, accessed in Dec 2012.
33. Kedik SA, Fedorov SV, Yanul NA, Prokhorova LV, Smirnova EV, Panov AV 2003. Medicinal plants: chromatographic determination of stevioside in raw plant material. Pharm Chem J 37: 19-22.
34. Ministério da Saúde 2012. Relação Nacional de Medicamentos quase dobra. http://portalsaude.saude.gov.br/portalsaude/noticia/4603/162/relacao-nacional-de-medicamentos-quase-dobra.html, accessed in Dec 2012.
35. Pauli G, Jaki B, Lankin D 2005. Quantitative H NMR: development and potential of a method for natural products analysis. J Nat Prod 68: 133-149.
36. Pauli G, Jaki U, Lankin D, Walter J, Burton I. In: Colegate S, Molyneux R (editors) 2008. Bioactive Natural Products. Boca Raton: CRC Press: p. 113-141.
37. Petrovick PR, Marques LC, De Paula IC 1999. New rules for phytopharmaceutical drug registration in Brazil. J Ethnopharmacol 66: 51-55.
38. Pianetti GA, 2012. Eleicão das Monografias de Fitoterápicos para a Farmacopéia Brasileira. Padrões de Referência e Métodos Analíticos em Insumos Vegetais e Medicamentos Fitoterápicos. Brasilia, Brazil.
39. Piovesan MF, Labra ME 2007. Institutional change and political decision-making in the creation of the Brazilian National Health Surveillance Agency. Cad Saude Publ 23: 1373-1382.
40. Reif K, Sievers H, Steffen J-P 2004. The role of chemical reference standards as analytical tools in the quality assessment of botanical materials - A European perspective. Herbal Gram 63: 38-43.
41. Röder E 1995. Medicinal plants in Europe containing pyrrolizidine alkaloids. Pharmazie 50: 83-98.
42. Ruparel P, Lockwood B 2011. The quality of commercially available herbal products. Nat Prod Commun 6: 733-744.
43. Sahoo N, Manchikanti P, Dey S 2010. Herbal drugs: Standards and regulation. Fitoterapia 81: 462-471
44. Schwarz M, Klier B, Sievers H 2009. Herbal Reference Standards. Planta Med 75: 689-703.
45. Thorpe R, Wadhwa M 2011. Intended use of reference products & WHO International Standards/Reference Reagents in the development of imilar Biological Products (Biosimilars). Biologicals 39: 262-265.
46. United States of America Congress 1994. Dietary Supplement Health and Education Act, Public Law 103-417. http://ods.od.nih.gov/About/DSHEA_Wording.aspx,accessed in Dec 2012.
47. th edition of the National Formulary (NF30). http://www.uspnf.com, accessed in Dec 2012.
48. Veiga-Jr VFV, Mello, JCP 2008. As monografi as sobre plantas medicinais. Rev Bras Farmacogn 18: 464-471.
49. WHO 1991. Guidelines for the Assessment of Herbal Medicines. World Health Organization, http://whqlibdoc.who.int/hq/1991/WHO_TRM_91.4.pdf, accessed in Dec 2012.
50. WHO 1995. Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Products. World Health Organization, WHO Technical Series, No. 850, 1995, Annex 3. http://www.nus.edu.sg/irb/Articles/WHO%20GCP%201995.pdf, accessed in Dec 2012.
51. th Report. World Health Organization http://apps.who.int/medicinedocs/en/d/Jh1792e/, accessed in Dec 2012.
52. th Report. World Health Organization, http://whqlibdoc.who.int/trs/who_trs_952_eng.pdf, accessed in Dec 2012.
53. World Health Organization Research Office for the Western Pacific 1993. Research Guidelines for Evaluating the Safety and Efficacy of Herbal Medicines. http://www.wpro.who.int/publications/docs/Research_Guidelines_Evaluating_the_Safety_and_Efficacy_Herbal_Medicines.pdf, accessed in Dec 2012.
54. Veit M, Wissel S 2007. Definitionen und Anforderungen an Referenzstandards in der Arzneimittelprüfung. Pharm Ind 69: 1475-1480.
55. Veit M, Wissel S 2008. Referenzstandards in der Arzneimittelprüfung. Pharm Ind 70: 135-138.
56. Vlietinck A, Pieters L, Apers S 2009. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of Herbal Medicinal Products in the European Union. Planta Med 75: 683-688.